


 Cite this: *RSC Adv.*, 2023, 13, 7848

# In-vial solid-phase extraction of polycyclic aromatic hydrocarbons in drug formulations stored in packaging containing rubber†

 Hao Yang,<sup>ab</sup> Yinmeng Ding,<sup>ab</sup> Ya Ding \*<sup>ab</sup> and Jing Liu \*<sup>ab</sup>

Polycyclic aromatic hydrocarbons (PAHs) are a class of ubiquitous and persistent organic compounds that are significantly teratogenic, carcinogenic and mutagenic. Rubber stoppers commonly used in sterile formulation packaging materials often contain carbon black as the additive to enhance mechanical strength. However, PAHs may be formed during the production of carbon black, which could cause the drug formulations to be contaminated when contacting with the rubber stopper, and then enter the patient's body. The determination of PAHs in drug formulations is challenging, due to their trace amounts and matrix interference. Therefore, sample pretreatment is necessary and important. In this work, a novel technique, named in-vial solid-phase extraction (IVSPE), was developed for the selective extraction and enrichment of 16 PAHs in pharmaceuticals. The coated sample vial was directly used as the container for the whole process of sample pretreatment. As the solid-phase adsorbent, the coating was prepared by successively modifying the inner surface of a sample vial with polydopamine film and octadecylamine. PAHs could be selectively extracted through  $\pi$ - $\pi$  stacking interaction and hydrophobic interaction, and then desorbed and enriched by a small amount of organic solvent. After systematic optimization of the coating preparation and the extraction process, the limits of detection and quantification of 16 PAHs were in the range of 0.002–0.60 ng mL<sup>-1</sup> and 0.007–2.00 ng mL<sup>-1</sup>, respectively. Good linearities and precision of six repeated injections were obtained. The recoveries at three spiked concentration levels in normal saline were in the range of 62.72–106.90% with the relative standard deviation between 0.83% and 6.78%. Finally, PAHs in normal saline and powders for injection were extracted by established IVSPE, followed by separation and detection with high-performance liquid chromatography with a fluorescence detector and diode array detector (HPLC-FLD/DAD). It is worth noting that the preparation conditions of the adsorbent in the IVSPE method are mild, simple and green. Moreover, IVSPE has the advantages of having few work steps and avoiding the risk of contamination, because no special instrumentation or sample transfer is required. IVSPE could also be used for the pretreatment of multiple samples at the same time, which is beneficial to practical applications.

Received 29th November 2022

Accepted 2nd March 2023

DOI: 10.1039/d2ra07582b

[rsc.li/rsc-advances](https://rsc.li/rsc-advances)

## 1 Introduction

Polycyclic aromatic hydrocarbons (PAHs) are a class of compounds formed by two or more fused aromatic rings, without a heteroatom or substituent.<sup>1,2</sup> Besides natural biosynthesis, the major source of PAHs is anthropogenic activities, such as the incomplete combustion of coal, petroleum, wood and organic polymers.<sup>3–5</sup> It has been paid a lot of attention that

many PAHs possess significant teratogenicity, carcinogenicity and mutagenicity<sup>6–9</sup>. Heavy occupational exposure to the mixtures of PAHs entails a substantial risk of lung, skin, or bladder cancer. The metabolites of certain PAHs could interact with DNA and are genotoxic, causing malignancies and heritable genetic damage in humans. In addition, PAHs can be biomagnified in the food chain and bioaccumulated *in vivo* because of their lipophilicity and low metabolic rate,<sup>10–13</sup> which can affect human health. Therefore, the US Environmental Protection Agency (USEPA) has recommended a list of 16 PAH compounds as the priority pollutants.

Humans are widely exposed to PAHs everyday through multiple ways, including respiratory system,<sup>14,15</sup> skin contact,<sup>16</sup> digestive system,<sup>17–19</sup> medicine<sup>1,20,21</sup> and so on. Therefore, the monitoring of PAHs in the environment, food and pharmaceuticals is an important measure to reduce the related

<sup>a</sup>Department of Pharmaceutical Analysis, China Pharmaceutical University, 24 Tongjiaxiang, Nanjing 210009, China. E-mail: dingya@cpu.edu.cn

<sup>b</sup>Key Laboratory of Drug Quality Control and Pharmacovigilance, Ministry of Education, China Pharmaceutical University, 24 Tongjiaxiang, Nanjing 210009, China. E-mail: liujing@cpu.edu.cn

† Electronic supplementary information (ESI) available. See DOI: <https://doi.org/10.1039/d2ra07582b>



diseases.<sup>22–24</sup> As the basic therapeutic products in clinic, drug formulations may introduce PAHs to patients if rubbers are used as the packaging materials.<sup>21,25</sup> It is because carbon black (CB) is the most commonly used as the reinforcing agent to reinforce the mechanical strength and increase the pigmentation capacity in the production of rubber.<sup>26</sup> And as a material produced by the incomplete combustion of biomass and fossil fuel,<sup>27</sup> CB is a known source of PAHs and has been considered possibly carcinogenic to humans by the International Agency for Research on Cancer.<sup>28</sup> This means PAHs could enter the body and impart adverse effect on human health through the rubber closures. Therefore, it is very important to detect PAHs in pharmaceutical formulations.

Gas chromatography (GC) and high-performance liquid chromatography (HPLC) with fluorescence detector (FLD), diode array detector (DAD) or mass spectrometer (MS) are the most frequently employed techniques for the determination of PAHs in different types of matrices.<sup>29–31</sup> In order to meet the needs of analytical instruments and sensitivity, sample pretreatment has already been used extensively for the extraction and preconcentration of the analytes in real samples, such as Soxhlet extraction,<sup>32</sup> potassium hydroxide saponification,<sup>33</sup> ultrasonic assisted treatment,<sup>34</sup> microwave assisted extraction,<sup>35</sup> pressurized liquid extraction,<sup>36</sup> liquid–liquid extraction,<sup>37</sup> liquid phase microextraction,<sup>1</sup> solid phase microextraction,<sup>38–40</sup> solid phase dispersive microextraction,<sup>41</sup> and magnetic solid-phase extraction (MSPE). There are some drawbacks with these methods, including the complex steps, time-consuming, large consumption of organic solvents, low extraction efficiency, excessive dependence on extraction conditions, and interference of co-eluting substances. Therefore, it is necessary to develop a simple, green and efficient pretreatment technology for the determination of PAHs.

Dopamine (DA), containing both catechol and amino groups, is a simple and widely used molecule for the inspired synthesis due to its self-polymerization. Under weak alkaline condition, DA molecules can be easily deposited on a variety of inorganic or organic substrates to form stable and hydrophilic polydopamine (PDA) film just like glue.<sup>42,43</sup> The self-polymerized procedure is environmentally friendly and mild. The formed PDA film which possesses an assortment of reactive functional groups could provide the anchors for the secondary conjugation of interesting functionalities without surface pretreatment. For example, the catechols are easily converted into highly reactive quinones, which can further react with thiols and amines *via* Michael type addition or Schiff base formation.<sup>44–46</sup> The PDA film is composed of roughly planar oligomers and can be used as the adsorbent for extracting aromatic compounds through  $\pi$ - $\pi$  stacking interaction and van der Waals forces. Wang *et al.* prepared PDA-coated Fe<sub>3</sub>O<sub>4</sub> nanoparticles (Fe<sub>3</sub>O<sub>4</sub>@PDA NPs) for the enrichment of 6 PAHs in the environmental water samples.<sup>47</sup> Ma *et al.* used Fe<sub>3</sub>O<sub>4</sub>@PDA NPs as an adsorbent and matrix for the detection of benzo(a)pyrene (BaP) by matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF-MS) in the tap water and lake water samples.<sup>48</sup> In these methods, Fe<sub>3</sub>O<sub>4</sub> NPs with sufficient magnetism need to be prepared first, which are susceptible to

aggregation. Moreover, external magnetic field is needed for the collection of the analytes. PDA-modified 3D nickel foam (NF@PDA) was also used as the adsorbent to extract PAHs from water samples.<sup>49</sup> It is necessary to take NF@PDA in and out of the sampling container using tweezers or the like, which is considered to increase the contamination risk of the analytes from the external environment.

In this study, we proposed in-vial SPE (IVSPE) technology for the sample extraction, and the vial that was often used for loading sample in HPLC was chosen as the medium to complete the whole pretreatment process without sample transfer after its internal surface modification. The schematic of the principle for the preparation of coating on the inner surface of vial was shown in Fig. 1. PDA film was first deposited on the inner wall of vial through oxidative self-polymerization. Then octadecylamine (ODA) was further grafted on the surface of formed PDA *via* Schiff base formation. Since there are abundant phenyls on PDA film and long alkyl chain of ODA, the composite layer of IVSPE is expected to offer strong adsorption affinity to PAHs, due to their  $\pi$ - $\pi$  stacking interaction, as well as hydrophobic interaction. After the optimization of the coating preparation and sample extraction, 16 priority-controlled PAHs could be simultaneously extracted efficiently. Finally, IVSPE coupled with HPLC-FLD/DAD was successfully used for the detection of PAHs in drug formulations, including normal saline and powders for injection.

## 2 Experimental

### 2.1 Reagents and materials

Dopamine Hydrochloride (DA·HCl, 98%) and octadecylamine (GC, >97%) were purchased from Shanghai Aladdin Biochemical Technology Co., Ltd. (China). Tris(hydroxymethyl)-amino methane (Tris, 99%) was obtained from Nanjing SunShine Biotechnology Co., Ltd. (China). Acetonitrile (ACN) was of HPLC grade and purchased from TEDIA (USA). Other chemicals were of analytical grade. The sample vials were obtained from ANW Technologies (China). The normal saline for injection (Shijiazhuang Four Drugs Co., Ltd., 0.9%), benzylpenicillin sodium for injection (Shandong Lukang Pharmaceutical Co., Ltd., 160 million units per 96 g) and omeprazole sodium for injection (Jiangsu Wuzhong Pharmaceutical Group Co., Ltd., 40 mg) were commercial products.

Standard mixtures of the 16 PAHs with 200  $\mu\text{g mL}^{-1}$  of each compound dissolved in acetonitrile (for HPLC analysis) was obtained from Manhage Bio-Technology Co., Ltd. (China). The 16 PAHs were naphthalene (NAP), acenaphthylene (ANY), acenaphthene (ANA), fluorene (FLU), phenanthrene (PHE), anthracene (ANT), fluoranthene (FLT), pyrene (PYR), benz[a]anthracene (BaA), chrysene (CHR), benzo[b]fluoranthene (BbF), benzo[k]fluoranthene (BkF), benzo[a]pyrene (BaP), indeno[1,2,3-*cd*]pyrene (IPY), dibenz[a,h]anthracene (DBA) and benzo[ghi]perylene (BPE). The PAHs stock solution was prepared with acetonitrile at the concentration of each at 2  $\mu\text{g mL}^{-1}$ , and kept at 4 °C in darkness. PAHs working solutions were prepared by the dilution of the stock solution.




Fig. 1 Schematic of the principle for the preparation of coating on the inner surface of vial.

## 2.2 HPLC analytical conditions

The HPLC analysis was performed on a SHIMADZU LC-20AT series HPLC system (Kyoto, Japan) with RF-20A fluorescent spectrophotometric detector and SPD-M20A photodiode array ultraviolet-visible light detector. A Zorbax Eclipse PAH (4.6 × 150 mm i.d., 5 μm, Agilent Technologies) column was used for PAHs separation. The column temperature was 30 °C. The mobile phase consisting of ACN and water was in gradient mode (Table 1). And the initial flow rate was 2 mL min<sup>-1</sup>. The injection volume was 20 μL. ANY was detected by DAD at 228 nm, and the other PAHs were detected by FLD. The excitation and emission wavelengths of FLD were summarized in Table 1.

## 2.3 Preparation of SPE vials

The procedure of preparation was shown in Fig. 2A. PDA film was formed through the self-polymerization of DA dissolved in

10 mM Tris buffer at pH 8.5. Firstly, 1 mL of DA solution was added into the vial. After mechanically shaken at 37 °C for 4 h, the solution was discarded. The vial was washed gently with acetonitrile and ultrapure water for 3 times, respectively. Then the above procedure was repeated to increase the thickness of PDA layer. After the formation of a stable PDA film on the inner wall of vial, 0.25 mg mL<sup>-1</sup> ODA solution in alcohol was added and mechanically shaken 2 h at 40 °C. Then, the remained solution was poured out, and the vial was washed for 3 times.

## 2.4 Characterization

A Quanta 250 FEG electron microscope (Thermo Scientific Inc., USA) was employed to record scanning electronic microscope (SEM) images of coating. The surface chemical component of coating was investigated by an attenuated total reflectance-Fourier transform infrared (ATR-FTIR) spectrometer (Nicolet iS50, Thermo Scientific Inc., USA).

Table 1 HPLC chromatographic conditions

Time (min)	Mobile phase water/acetonitrile	FLD wavelength (nm)		Detected compounds
		Excitation	Emission	
0.01	60/40	275	350	NAP, ANA, FLU, PHE
9.50	60/40	260	420	ANT
10.50	60/40	270	440	FLT, PYR
13.00	60/40	260	420	BaA, CHR
15.25	60/40	290	430	BbF, BkF, BaP, IPY, DBA
20.00	0/100			
20.20	0/100	250	500	BPE
22.50	0/100			
25.50	60/40			
28.00	60/40			




Fig. 2 Schematic illustration of the preparation and extraction procedure of IVSPE.

### 2.5 Extraction procedure of IVSPE

As shown in Fig. 2B, 1.5 mL of the sample solution was added into the prepared vial and shaken at room temperature. When the adsorption process was completed, the solution was poured out. And the vial was washed with 1 mL of ultrapure water for 3 times. Then the target compounds were desorbed from the adsorbent with 300  $\mu\text{L}$  of acetonitrile by shaken at room temperature.

### 2.6 Preparation of real samples

**2.6.1 Preparation of the normal saline.** The normal saline was accurately transferred 1.50 mL into the prepared IVSPE vial and shaken for 60 min at room temperature. Then the saline was poured out, and the vial was cleaned three times with ultrapure water. After that, 300  $\mu\text{L}$  of acetonitrile was added and shaken at 200 rpm for 3 h.

**2.6.2 Preparation of the powders for injection.** Because both powders for injection were water-soluble, the sample solution was prepared with ultrapure water at the concentration of 200  $\text{mg mL}^{-1}$  for penicillin sodium and 20  $\text{mg mL}^{-1}$  for omeprazole sodium, respectively. Then the sample solution was

extracted and eluted following the previously described procedure of the normal saline.

## 3 Results and discussion

It has been proven that DA dissolved in Tris buffer at pH 8.5 could self-polymerize to form PDA on the surfaces of almost various substrates under non-toxic conditions. Moreover, PDA coating is easily to be further modification. Owing to the above advantages, we developed the sample vial coated with PDA and ODA for simple and selective extraction of PAHs.

In order to achieve high efficiency of extraction, the parameters in IVSPE process were designed and optimized by control variable method, including the preparation conditions of coating and the extraction conditions of PAHs.

### 3.1 Optimization of the preparation of PDA coating

**3.1.1 Effect of the concentration of DA.** The thickness of PDA film is closely related to the amount of DA.<sup>50</sup> Thus, it is necessary to investigate the effect of concentration of DA on the extraction efficiency. As shown in Fig. 3, the recoveries of most PAHs became larger with the increase in the




Fig. 3 Recoveries of 16 PAHs with different concentration of DA solution ( $n = 6$ ).




Fig. 4 Recoveries of 16 PAHs with different numbers of PDA layer ( $n = 6$ ).

concentration of DA to  $5 \text{ mg mL}^{-1}$ . When the concentration was further increased to  $6 \text{ mg mL}^{-1}$ , the recoveries were remained at the same level or even decreased. Therefore,  $5 \text{ mg mL}^{-1}$  DA solution was chosen for the preparation of PDA coating in sample vial.

**3.1.2 Effect of the number of PDA layers.** As the core of IVSPE, the amount of solid adsorbent could be manually controlled by changing the deposition times of PDA in sample vial. To obtain a stable and uniform coating, the DA solution was exchanged every 4 h. It could be observed that the color of vial became darker and darker as the number of PDA layer increased from one to nine (Fig. S1<sup>†</sup>). The morphologies of PDA-modified vials were investigated by SEM characterization. As shown in Fig. S2A,<sup>†</sup> the inner surface of bare vial was smooth and clean. After modified layer by layer (Fig. S2B–G<sup>†</sup>), the inner surface was covered with more and more visible aggregates, which indicated the successful immobilization of each layer of PDA. Meanwhile, it also suggested the positive correlation between the increase in the deposited amounts and the number of coatings. According to the cross-section SEM images of the vials (Fig. S2H and I<sup>†</sup>), the PDA coating was clearly discerned on the inner wall of the vial. The extraction effect of different layers was illustrated in Fig. 4. The recoveries of most PAHs were in the range of 71.89–89.00%

with eight repetitive coatings, except for NAP. It was probably because the more layers, the greater the adsorbent amount and the larger the extraction capacity.

### 3.2 Modification of PDA coating

According to the above results, the recovery of NAP was below 50% even after optimizing the preparation conditions of PDA coating. The reason is probably due to there are only two aromatic rings in the structure of NAP, and the  $\pi$ - $\pi$  stacking interaction between PDA coating and NAP is not sufficiently strong. In order to improve the extraction of NAP, ODA containing long alkyl chain was used to further modify the surface of PDA coating *via* Schiff base reaction. After the graft of ODA, the hydrophobicity of PDA coating was increased. It was benefit for the adsorption of hydrophobic PAHs, especially for NAP.

In order to prove the post-modification of ODA, ATR-FTIR was used to characterize the surface chemical component of the coating. As shown in Fig. S3,<sup>†</sup> two new absorption peaks located at around  $2910 \text{ cm}^{-1}$  and  $2840 \text{ cm}^{-1}$  appeared after ODA was introduced, which were related to the stretching vibration of C–H in ODA molecules. The concentration and the reaction time of ODA could affect the surface properties of




Fig. 5 Recovery of 16 PAHs with the modification of ODA at different concentrations (A) and for different reaction time (B) ( $n = 6$ ).



coating, and further impact the extraction efficiency of IVSPE on different PAHs. According to Fig. 5A, the recoveries of all PAHs were increased gradually when the concentration of ODA was varied from 0.05 to 0.25 mg mL<sup>-1</sup>. In particular, the recovery of NAP could reach 65.49%, which is significantly higher than that of using PDA coating alone. With the further increase of concentration, no improvement of recovery was observed, and the recoveries of high-ring PAHs even decreased obviously. As mentioned above, excess modification with ODA might inhibit the adhesion between PDA coating and high-ring PAHs through  $\pi$ - $\pi$  stacking interaction. Clearly, there is a compromise of the recovery between low-ring and high-ring PAHs.<sup>51–53</sup> Considering the recoveries of all 16 PAHs within an acceptable range, 0.25 mg mL<sup>-1</sup> ODA was selected for further optimization. Next, we investigated the effect of reaction time on the recoveries of PAHs as the time was varied from 0.5 h to 4 h. As shown in Fig. 5B, 2 h was sufficient to achieve satisfactory extraction efficiency for all PAHs.

### 3.3 Optimization of extraction conditions

The extraction of PAHs with good reproducibility by the established IVSPE mode needs enough contact time between the targets and adsorbent for reaching the equilibrium. Therefore, different extraction time ranging from 30 min to 90 min were studied. The result in Fig. 6A showed that 60 min was sufficient for all the PAHs to achieve satisfactory extraction efficiency. The elution time can also affect the extraction efficiency significantly. Fig. 6B illustrated the effect of elution time on the recovery of 16 PAHs in the range of 2–5 h. The recovery was not greatly increased after 3 h.

### 3.4 Method validation

The established method of IVSPE coupled with HPLC-FLD/DAD was validated for the determination of PAHs. The limit of detection (LOD) and the limit of quantification (LOQ) were calculated based on the signal-to-noise ratio (S/N) of 3 : 1 and 10 : 1, respectively. The LODs of 16 PAHs were in the range of 0.002–0.60 ng mL<sup>-1</sup>, and LOQs were determined to be 0.007–2.00 ng mL<sup>-1</sup>. In addition, good linearities were exhibited for PAHs, and all of the correlation coefficients (*r*) were more than 0.999. The relative standard deviations of six replicate

Table 2 Validation data of the proposed method for the determination of 16 PAHs

PAHs	Linearity range (ng mL <sup>-1</sup> )	LOD (ng mL <sup>-1</sup> )	LOQ (ng mL <sup>-1</sup> )	RSD (%) ( <i>n</i> = 6)
NAP	0.10–50.0	0.020	0.08	0.22
ANY	2.00–50.0	0.60	2.00	1.51
ANA	0.02–50.0	0.007	0.02	0.20
FLU	0.02–50.0	0.007	0.02	0.31
PHE	0.10–40.0	0.020	0.08	0.31
ANT	0.01–40.0	0.002	0.007	0.24
FLT	0.02–50.0	0.007	0.02	0.27
PYR	0.10–50.0	0.020	0.08	0.54
BaA	0.02–50.0	0.007	0.02	1.15
CHR	0.01–50.0	0.002	0.007	0.79
BbF	0.01–50.0	0.002	0.007	0.06
BkF	0.01–50.0	0.002	0.007	0.06
BaP	0.01–50.0	0.002	0.007	0.09
IPY	0.01–50.0	0.002	0.007	0.19
DBA	0.02–50.0	0.007	0.02	0.18
BPE	2.00–50.0	0.60	2.00	5.40

injections (RSDs, *n* = 6) showed good precision with the range of 0.06–5.40%. Therefore, the established IVSPE-HPLC method is effective and sensitive for the detection of 16 PAHs. These validation results mentioned above were summarized in Table 2. Moreover, we investigated the stability of the prepared vials by testing their extraction ability to PAHs after the vials were stored for one month. Six vials were chosen at random, and the recoveries of 16 kinds of PAHs were in the range of 60–95% with the reproducibility lower than 10%. These results suggested good stability of the SPE vials.

### 3.5 Application to real samples

To further demonstrate the feasibility of the proposed analytical methodology, it was used for the determination of PAHs in real samples, including normal saline, omeprazole sodium and benzylpenicillin sodium powders for injection. Fig. 7 showed the chromatograms of PAHs in three real samples and 10 ng mL<sup>-1</sup> PAHs standard solution. No PAHs were detected in the selected drug formulations. In addition, the recoveries of PAHs in normal saline were measured at three spiked levels in




Fig. 6 Recovery of 16 PAHs at different extraction time (A) and at different elution time (B) (*n* = 6).




Fig. 7 HPLC chromatograms of (A) 10 ng mL<sup>-1</sup> PAHs standard solution (B) normal saline (C) 20 mg mL<sup>-1</sup> omeprazole sodium, and (D) 200 mg mL<sup>-1</sup> benzylpenicillin sodium. Peak identities: 1, NAP; 2, ANY; 3, ANA; 4, FLU; 5, PHE; 6, ANT; 7, FLT; 8, PYR; 9, BaA; 10, CHR; 11, BbF; 12, BkF; 13, BaP; 14, IPY; 15, DBA; 16, BPE.

Table 3 Recoveries of PAHs in normal saline using the proposed method ( $n = 3$ )

Analytes	Spiked sample		6 ng mL <sup>-1</sup>		10 ng mL <sup>-1</sup>	
	2 ng mL <sup>-1</sup>		Recovery%	RSD%	Recovery%	RSD%
NAP	76.01 ± 2.83	3.72	71.27 ± 2.17	3.05	67.20 ± 2.60	3.87
ANY	100.86 ± 3.23	3.21	97.27 ± 2.87	2.95	95.97 ± 2.40	2.50
ANA	100.46 ± 2.43	2.42	96.39 ± 1.94	2.01	94.82 ± 1.57	1.66
FLU	104.61 ± 1.56	1.49	101.26 ± 1.10	1.08	98.88 ± 1.22	1.23
PHE	106.90 ± 1.44	1.35	98.52 ± 0.57	0.58	96.30 ± 1.76	1.83
ANT	105.88 ± 1.70	1.61	100.87 ± 1.52	1.51	97.85 ± 1.56	1.59
FLT	100.42 ± 1.59	1.58	94.37 ± 1.48	1.57	89.05 ± 1.60	1.80
PYR	97.58 ± 1.20	1.23	95.13 ± 1.51	1.59	86.24 ± 1.65	1.92
BaA	88.04 ± 1.41	1.60	94.69 ± 2.73	2.88	91.82 ± 1.72	1.87
CHR	91.17 ± 1.92	2.10	97.69 ± 1.88	1.92	96.07 ± 1.64	1.71
BbF	74.81 ± 2.36	3.16	87.03 ± 3.73	4.29	83.83 ± 2.68	3.20
BkF	85.96 ± 1.56	1.82	92.31 ± 2.46	2.67	92.71 ± 1.89	2.04
BaP	76.32 ± 1.61	2.11	85.18 ± 3.51	4.12	104.89 ± 4.29	4.09
IPY	84.42 ± 1.75	2.07	86.44 ± 4.95	5.73	86.36 ± 2.35	2.72
DBA	62.72 ± 2.25	6.78	65.99 ± 0.55	0.83	74.43 ± 1.37	1.85
BPE	73.78 ± 2.96	4.02	73.22 ± 4.86	6.64	71.63 ± 3.82	5.34

Table 4 Comparison of different methods for the determination of PAHs in drug formulations

Kinds of PAHs	Sample pretreatment	Analytical method	LOD (ng mL <sup>-1</sup> )	LOQ (ng mL <sup>-1</sup> )	Recovery (%)	Ref.
16	Cold filtration	GC-MS	0.7–6.0 <sup>a</sup>	4–30 <sup>a</sup>	—	29
12	SPE	HPLC-UVD/FLD	10–110	40–330	85.6–122.8	30
16	SPE	HPLC-DAD	1–60	3–167	75–120	31
16	IVSPE	HPLC-FLD/DAD	0.002–0.6	0.007–2.00	62.72–106.90	This work

<sup>a</sup> The unit is ng/inhaler.

triplicate. The recoveries and RSDs were used to evaluate the accuracy and precision of this method for a real sample. The results in Table 3 showed the average recoveries of PAHs were in the range of 62.70–106.90% with RSDs below 6.78%. These results implied that the developed method could be applied to determine PAHs in drug matrix.

There are few studies on the determination of PAHs in drug formulations. Through literature review, the parameters in this work were compared with others, such as LOD, LOQ and recovery. As shown in Table 4, 16 PAHs could be simultaneously determined by our established method with higher sensitivity and acceptable recovery. It is indicated that IVSPE combined with HPLC-FLD/DAD has a promising application in the analysis of PAHs in pharmaceutical preparations.

## 4 Conclusion

In this study, a simple, facile and environmentally-friendly pretreatment method, named IVSPE, was established based on the self-polymerization of DA and the post-modification with ODA. The sample vial was coated with PDA film on the inner surface, and then the ODA was grafted on PDA *via* Schiff base reaction. After optimizing the parameters of PDA coating, modification of ODA and extraction conditions, the prepared vials exhibited satisfactory extraction efficiency for 16 PAHs. In this IVSPE method, no special instruments are required. The operation steps are simplified, and there is no need to transfer the sample several times. This is very helpful to reduce sample loss and the risk of contamination. Moreover, the extraction and desorption in different vials can be operated at the same time, which will save time for sample pretreatment. Coupled with the detection of HPLC-FLD/DAD, the determination results of 16 PAHs showed excellent analytical performance. The LODs and LOQs were in the range of 0.002–0.60 ng mL<sup>-1</sup> and 0.007–2.00 ng mL<sup>-1</sup>, respectively. And the linear relationship was good for all PAHs within the concentration range between 0.01 and 50 ng mL<sup>-1</sup>. The spiked recovery of normal saline at three concentration levels was 62.72–106.90% with high precision. Finally, the developed method was successfully applied for the determination of PAHs in drug formulations stored in packaging containing rubber.

## Conflicts of interest

The authors declare that there are no conflicts of interest.

## Acknowledgements

This work was supported by grants from the National Key Research and Development Program of China (No. 2019YFC1605400), and the Natural Science Foundation of Jiangsu Province (No. BK20200567).

## References

- 1 W. Deng, A. Huang, Q. Zheng, L. Yu, X. Li, H. Hu and Y. Xiao, *Food Chem.*, 2021, **352**, 129331.
- 2 G. R. Sampaio, G. M. Guizzellini, S. A. da Silva, A. P. de Almeida, A. C. C. Pinaffi-Langley, M. M. Rogero, A. C. de Camargo and E. Torres, *Int. J. Mol. Sci.*, 2021, **22**, 6010.
- 3 H. I. Abdel-Shafy and M. S. M. Mansour, *Egypt. J. Pet.*, 2016, **25**, 107–123.
- 4 A. K. Haritash and C. P. Kaushik, *J. Hazard. Mater.*, 2009, **169**, 1–15.
- 5 M. Lv, X. Luan, C. Liao, D. Wang, D. Liu, G. Zhang, G. Jiang and L. Chen, *Nat. Sustain.*, 2020, **3**, 878–884.
- 6 W. Xue and D. Warshawsky, *Toxicol. Appl. Pharmacol.*, 2005, **206**, 73–93.
- 7 S. Amirdivani, N. Khorshidian, M. Ghobadi Dana, R. Mohammadi, A. M. Mortazavian, S. L. Quiterio de Souza, H. Barbosa Rocha and R. Raices, *Int. J. Dairy Technol.*, 2019, **72**, 120–131.
- 8 A. M. Girelli, D. Sperati and A. M. Tarola, *Food Addit. Contam., Part A*, 2014, **31**, 703–710.
- 9 R. Stading, G. Gastelum, C. Chu, W. Jiang and B. Moorthy, *Semin. Cancer Biol.*, 2021, **76**, 3–16.
- 10 V. Bansal and K. H. Kim, *Environ. Int.*, 2015, **84**, 26–38.
- 11 Y. Sun, K. Yan, S. Wu and G. Gong, *Food Control*, 2020, **113**, 107197.
- 12 M. C. R. Sola, A. G. Santos, S. T. Martinez, M. M. Nascimento, G. O. da Rocha and J. B. de Andrade, *Sci. Rep.*, 2020, **10**, 3465.
- 13 N. D. Dat and M. B. Chang, *Sci. Total Environ.*, 2017, **609**, 682–693.
- 14 A. G. Santos, A. C. Regis, G. O. da Rocha, A. Bezerra Mde, R. M. de Jesus and J. B. de Andrade, *J. Chromatogr. A*, 2016, **1435**, 6–17.
- 15 G. L. Stroher, N. R. Poppi, J. L. Raposo and J. B. Gomes de Souza, *Microchem. J.*, 2007, **86**, 112–118.
- 16 S. W. Wang, K. H. Hsu, S. C. Huang, S. H. Tseng, D. Y. Wang and H. F. Cheng, *J. Food Drug Anal.*, 2019, **27**, 815–824.
- 17 A. G. Gorshkov, O. N. Izosimova and O. V. Kustova, *J. Anal. Chem.*, 2019, **74**, 771–777.
- 18 S. Y. Lee, J. Y. Lee and H. S. Shin, *Toxicol. Res.*, 2015, **31**, 265–271.
- 19 V. A. Garcia Londono, C. M. Reynoso and S. Resnik, *Food Addit. Contam., Part B*, 2017, **10**, 284–291.
- 20 D. Bohrer, C. Viana, M. M. Barichello, J. F. de Moura, L. M. de Carvalho and P. C. Nascimento, *JPEN, J. Parenter. Enteral Nutr.*, 2017, **41**, 1037–1044.
- 21 M. M. Barichello, D. Bohrer, C. Viana, L. M. Carvalho and P. C. Nascimento, *J. AOAC Int.*, 2017, **100**, 1070–1076.
- 22 X. Song, J. Li, S. Xu, R. Ying, J. Ma, C. Liao, D. Liu, J. Yu and L. Chen, *Talanta*, 2012, **99**, 75–82.
- 23 J. Pang, D. Yuan and X. Huang, *J. Chromatogr. A*, 2018, **1571**, 29–37.
- 24 L. Han, Y. Sapozhnikova and S. J. Lehotay, *Anal. Chim. Acta*, 2014, **827**, 40–46.
- 25 D. L. Norwood, D. Prime, B. P. Downey, J. Creasey, S. K. Sethi and P. Haywood, *J. Pharm. Biomed. Anal.*, 1995, **13**, 293–304.
- 26 S. Praveen, P. K. Chattopadhyay, P. Albert, V. G. Dalvi, B. C. Chakraborty and S. Chattopadhyay, *Composites, Part A*, 2009, **40**, 309–316.



- 27 Y. Qi, W. Fu, J. Tian, C. Luo, S. Shan, S. Sun, P. Ren, H. Zhang, J. Liu, X. Zhang and X. Wang, *Nat. Commun.*, 2020, **11**, 5051.
- 28 A. V. Ramanakumar, M. E. Parent, B. Latreille and J. Siemiatycki, *Int. J. Cancer*, 2008, **122**, 183–189.
- 29 D. L. Norwood, D. Prime, B. P. Downey, J. Creasey, S. K. Sethi and P. Haywood, *J. Pharm. Biomed. Anal.*, 1995, **13**, 293–304.
- 30 D. Bohrer, C. Viana, M. M. Barichello, J. F. de Moura, L. M. de Carvalho and P. C. Nascimento, *JPEN, J. Parenter. Enteral Nutr.*, 2017, **41**, 1037–1044.
- 31 M. M. Barichello, D. Bohrer, C. Viana, L. M. Carvalho and P. C. Nascimento, *J. AOAC Int.*, 2017, **100**, 1070–1076.
- 32 L. R. Bordajandi, G. Gomez, E. Abad, J. Rivera, M. D. Fernandez-Baston, J. Blasco and M. J. Gonzalez, *J. Agric. Food Chem.*, 2004, **52**, 992–1001.
- 33 B. M. Lee and G. A. Shim, *J. Toxicol. Environ. Health, Part A*, 2007, **70**, 1391–1394.
- 34 H. Kataoka, A. Ishizaki and K. Saito, *Chim. Oggi – Chem. Today*, 2010, **28**, 21–24.
- 35 T. Pena, L. Pensado, C. Casais, C. Mejuto, R. Phan-Tan-Luu and R. Cela, *J. Chromatogr. A*, 2006, **1121**, 163–169.
- 36 I. A. Titaley, U. Eriksson and M. Larsson, *J. Chromatogr. A*, 2020, **1618**, 460896.
- 37 A. Filipkowska, L. Lubecki and G. Kowalewska, *Anal. Chim. Acta*, 2005, **547**, 243–254.
- 38 Y. Tian, M. Sun, X. Wang, C. Luo and J. Feng, *Chromatographia*, 2018, **81**, 1053–1061.
- 39 M. D. Guillen and P. Sopolana, *J. Dairy Sci.*, 2005, **88**, 13–20.
- 40 J. Feng, M. Sun, X. Wang, Y. Tian, C. Luo and J. Feng, *Chromatographia*, 2018, **81**, 1287–1292.
- 41 N. Yazdanfar, M. Shamsipur, M. Ghambarian and A. Esrafil, *Chromatographia*, 2018, **81**, 487–499.
- 42 X. Fan, Z. Yuan, C. Shou, G. Fan, H. Wang, F. Gao, Y. Rui, K. Xu and P. Yin, *Int. J. Nanomed.*, 2019, **14**, 9631–9645.
- 43 H. Lee, S. M. Dellatore, W. M. Miller and P. B. Messersmith, *Science*, 2007, **318**, 426–430.
- 44 J. Ran, M. He, W. Li, D. Cheng and X. Wang, *Polymers*, 2018, **10**, 495.
- 45 P. G. Ingole, W. Choi, K. H. Kim, C. H. Park, W. K. Choi and H. K. Lee, *Chem. Eng. J.*, 2014, **243**, 137–146.
- 46 E. Faure, C. Falentin-Daudre, C. Jerome, J. Lyskawa, D. Fournier, P. Woisel and C. Detrembleur, *Prog. Polym. Sci.*, 2013, **38**, 236–270.
- 47 Y. Wang, S. Wang, H. Niu, Y. Ma, T. Zeng, Y. Cai and Z. Meng, *J. Chromatogr. A*, 2013, **1283**, 20–26.
- 48 Y. R. Ma, X. L. Zhang, T. Zeng, D. Cao, Z. Zhou, W. H. Li, H. Niu and Y. Q. Cai, *ACS Appl. Mater. Interfaces*, 2013, **5**, 1024–1030.
- 49 Y. Cai, Z. Yan, M. Yang, X. Huang, W. Min, L. Wang and Q. Cai, *J. Chromatogr. A*, 2016, **1478**, 2–9.
- 50 V. Ball, D. D. Frari, V. Toniazzo and D. Ruch, *J. Colloid Interface Sci.*, 2012, **386**, 366–372.
- 51 S. Nagamine, Y. Mizuno, Y. Hikima, K. Okada, L. Wang and M. Ohshima, *J. Appl. Polym. Sci.*, 2021, **138**, 49851.
- 52 G. K. Gaurav, T. Mehmood, M. Kumar, L. Cheng, K. Sathishkumar, A. Kumar and D. Yadav, *J. Contam. Hydrol.*, 2021, **236**, 103715.
- 53 H. Y. Li, P. P. Gao and H. G. Ni, *Sci. Total Environ.*, 2019, **665**, 11–17.